TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder
Brief Summary: The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder


Options:
A: Arm Label: Sertraline Liquid Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sertraline Liquid Placebo | Arm Label: Sertraline Active Medication; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Intervention Type: DRUG; Name: Sertraline Liquid Placebo; Assigned to Arm(s): Sertraline Liquid Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): Sertraline Active Medication
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole
D: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder
Brief Summary: The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole
B: Arm Label: Arbaclofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder
Brief Summary: The objective of this study is to investigate the efficacy and safety of aripiprazole orally administered over a period of 8 weeks in pediatric patients with Autistic Disorder


Options:
A: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A
B: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole
D: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Achieving Energy Balance in Overweight Post Partum Teens
Brief Summary: This proposal will test Balance Adolescent Lifestyle Activities and Nutrition Choices for Energy (BALANCE), a multilevel intervention administered through Parents as Teachers (PAT) and designed to reduce overweight in postpartum teens. The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Students for Nutrition and eXercise; Type: EXPERIMENTAL; Interventions: Behavioral: Students for Nutrition and eXercise | Intervention Type: BEHAVIORAL; Name: Students for Nutrition and eXercise; Assigned to Arm(s): Students for Nutrition and eXercise
B: Arm Label: BALANCE; Type: EXPERIMENTAL; Interventions: Behavioral: BALANCE | Intervention Type: BEHAVIORAL; Name: BALANCE; Assigned to Arm(s): BALANCE
C: Arm Label: Group 1:; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care management | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Standard care management | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Behavioral: The strengthened care management | Intervention Type: BEHAVIORAL; Name: Standard care management; Assigned to Arm(s): Group 1:, Group 2 | Intervention Type: BEHAVIORAL; Name: The strengthened care management; Assigned to Arm(s): Group 3
D: Arm Label: COPE/Healthy Lifestyles TEEN Program; Type: EXPERIMENTAL; Interventions: Behavioral: COPE/Healthy Lifestyles TEEN Program. | Arm Label: Healthy Teens Attention Control Program; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Healthy Teens Attention Control Program | Intervention Type: BEHAVIORAL; Name: COPE/Healthy Lifestyles TEEN Program.; Assigned to Arm(s): COPE/Healthy Lifestyles TEEN Program | Intervention Type: BEHAVIORAL; Name: Healthy Teens Attention Control Program; Assigned to Arm(s): Healthy Teens Attention Control Program

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C Higher or Equal to 160mg/dL With Their Lipid-Modifying Therapy
Brief Summary: Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).

Primary Objective of the study:

To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.

Secondary Objectives:

* To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points
* To evaluate the effects of alirocumab on other lipid parameters
* To evaluate the safety and tolerability of alirocumab


Options:
A: Arm Label: Alirocumab 75 mg/up to 150 mg; Type: EXPERIMENTAL; Interventions: Drug: LMT (atorvastatin, simvastatin, or rosuvastatin), Drug: alirocumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LMT (atorvastatin, simvastatin, or rosuvastatin); Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: alirocumab; Assigned to Arm(s): Alirocumab 75 mg/up to 150 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bococizumab (PF-04950615; RN316); Type: EXPERIMENTAL; Interventions: Drug: Bococizumab (PF-04950615; RN316) | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bococizumab (PF-04950615; RN316); Assigned to Arm(s): Bococizumab (PF-04950615; RN316) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Alirocumab 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 150 mg Q2W, Placebo Q2W
D: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: OTHER; Name: Diet Only; Assigned to Arm(s): Evolocumab, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of P6 Acupressure in Reducing Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy. - a Randomized, Double-blinded, Placebo Controlled Study.
Brief Summary: The aim of this study is to investigate if P6 acupressure may reduce postoperative nausea and vomiting in neurosurgical patients undergoing craniotomy.


Options:
A: Arm Label: Electroacupuncture; Type: EXPERIMENTAL; Interventions: Procedure: Electroacupuncture | Arm Label: Non-electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Procedure: non-electroacupuncture | Intervention Type: PROCEDURE; Name: non-electroacupuncture; Assigned to Arm(s): Non-electroacupuncture | Intervention Type: PROCEDURE; Name: Electroacupuncture; Assigned to Arm(s): Electroacupuncture
B: Arm Label: Acustimulation; Type: EXPERIMENTAL; Interventions: Device: Acustimulation | Arm Label: Standard treatment group; Type: NO_INTERVENTION; Interventions: Device: Acustimulation | Intervention Type: DEVICE; Name: Acustimulation; Assigned to Arm(s): Acustimulation, Standard treatment group
C: Intervention Type: DEVICE; Name: Acupressure; Assigned to Arm(s): N/A
D: Arm Label: P6 acupressure group; Type: ACTIVE_COMPARATOR; Interventions: Device: P6 acupressure band | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo band | Intervention Type: DEVICE; Name: P6 acupressure band; Assigned to Arm(s): P6 acupressure group | Intervention Type: OTHER; Name: Placebo band; Assigned to Arm(s): Placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis
Brief Summary: This was a multiple dose, dose escalation study designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of patisiran (ALN-TTR02) in participants with transthyretin (TTR) mediated amyloidosis (ATTR).


Options:
A: Arm Label: Open-Label; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tafamidis | Intervention Type: DRUG; Name: Tafamidis; Assigned to Arm(s): Open-Label
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fx-1006A | Intervention Type: DRUG; Name: Fx-1006A; Assigned to Arm(s): 1
C: Arm Label: patisiran (ALN-TTR02); Type: ACTIVE_COMPARATOR; Interventions: Drug: patisiran (ALN-TTR02) | Arm Label: Sterile Normal Saline (0.9% NaCl); Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile Normal Saline (0.9% NaCl) | Intervention Type: DRUG; Name: patisiran (ALN-TTR02); Assigned to Arm(s): patisiran (ALN-TTR02) | Intervention Type: DRUG; Name: Sterile Normal Saline (0.9% NaCl); Assigned to Arm(s): Sterile Normal Saline (0.9% NaCl)
D: Arm Label: Patisiran (ALN-TTR02); Type: EXPERIMENTAL; Interventions: Drug: Patisiran | Intervention Type: DRUG; Name: Patisiran; Assigned to Arm(s): Patisiran (ALN-TTR02)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures
Brief Summary: The purpose of this study is to confirm the efficacy and safety of perampanel compared to placebo in patients with refractory partial-onset seizures


Options:
A: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): Placebo
B: Arm Label: Perampanel; Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Perampenal (Core Study); Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Arm Label: Placebo (Core Study); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Perampanel (Extension Phase); Type: EXPERIMENTAL; Interventions: Drug: Perampanel | Intervention Type: DRUG; Name: Perampanel; Assigned to Arm(s): Perampanel (Extension Phase), Perampenal (Core Study) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (Core Study)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: E2007 (perampanel) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: E2007 (perampanel); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis
Brief Summary: Relative Bioavailability Comparison study


Options:
A: Arm Label: psoriatic arthritis (PsA) questionnaire; Type: NO_INTERVENTION; Interventions: Procedure: lab draws and imaging | Intervention Type: PROCEDURE; Name: lab draws and imaging; Assigned to Arm(s): psoriatic arthritis (PsA) questionnaire
B: Arm Label: Intensive management; Type: EXPERIMENTAL; Interventions: Drug: Intensive management or Tight control | Arm Label: Standard management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard management - Control group | Intervention Type: DRUG; Name: Intensive management or Tight control; Assigned to Arm(s): Intensive management | Intervention Type: DRUG; Name: Standard management - Control group; Assigned to Arm(s): Standard management
C: Arm Label: 10 mg Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 15 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 20 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Arm Label: 25 mg MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): 10 mg Methotrexate (MTX), 15 mg MTX, 20 mg MTX, 25 mg MTX
D: Arm Label: Treatment Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Golimumab | Arm Label: Treatment Group 2: Golimumab; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Golimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Treatment Group 1: Placebo, Treatment Group 2: Golimumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE)
Brief Summary: Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for patients with acute deep vein thrombosis (DVT).

The main goal is to analyze long-term safety in the use of rivaroxaban in the treatment of acute DVT in routine clinical practice.


Options:
A: Arm Label: Conventional anticoagulation therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Ekos Endowave system thrombolysis; Type: EXPERIMENTAL; Interventions: Device: Ekos endowave system thrombolysis | Intervention Type: DEVICE; Name: Ekos endowave system thrombolysis; Assigned to Arm(s): Ekos Endowave system thrombolysis
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I
C: Arm Label: LMWH; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparine calcium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: nadroparine calcium; Assigned to Arm(s): LMWH | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1; Type: N/A; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Group 2; Type: N/A; Interventions: Drug: Standard of care | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): Group 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Community Study of the Effectiveness of Misoprostol for PPH Treatment at the Community Level (Home Births Attended by Primary Care Unit Staff) in Etay El Barood and Kafr El Dawar Districts (El Beheira Governorate), Egypt
Brief Summary: This randomized controlled community-based trial will assess the effectiveness of administration of 800 mcg sublingual misoprostol with standard of care vs. placebo with standard of care for postpartum hemorrhage treatment at the community level, primarily home births attended by primary health care unit (PHU) staff in Etay El Barood and Kafr El Dawar districts (El Beheira governorate), Egypt. Standard of care per national guidelines in this setting is referral to a higher level health facility.


Options:
A: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Other: Misoprostol + referral | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo + referral | Intervention Type: OTHER; Name: Misoprostol + referral; Assigned to Arm(s): Misoprostol | Intervention Type: OTHER; Name: Placebo + referral; Assigned to Arm(s): Placebo
B: Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): misoprostol
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Community Engagement, Device: PIERS on the Move mHealth decision aid, Drug: Magnesium Sulfate, Drug: Methyldopa | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Engagement; Assigned to Arm(s): Intervention | Intervention Type: DEVICE; Name: PIERS on the Move mHealth decision aid; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): Intervention | Intervention Type: DRUG; Name: Methyldopa; Assigned to Arm(s): Intervention
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Controlled Pilot Study on Safety of Hypertonic Saline as Preventive Inhalation Therapy in Newborns and Infants With Cystic Fibrosis
Brief Summary: The purpose of this study is to assess whether 6% hypertonic saline (HS) is a safe and effective preventive therapy in newborns and infants with cystic fibrosis (CF).


Options:
A: Arm Label: Hypertonic saline; Type: EXPERIMENTAL; Interventions: Drug: Hypertonic Saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hypertonic Saline; Assigned to Arm(s): Hypertonic saline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: eRapid Nebulizer; Type: EXPERIMENTAL; Interventions: Drug: dornase alfa [Pulmozyme®] | Arm Label: Jet Nebulizer; Type: ACTIVE_COMPARATOR; Interventions: Drug: dornase alfa [Pulmozyme®] | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): eRapid Nebulizer | Intervention Type: DRUG; Name: dornase alfa [Pulmozyme®]; Assigned to Arm(s): Jet Nebulizer
C: Arm Label: Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 6% Hypertonic Saline (HS), 4mL | Arm Label: Isotonic Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS), 4mL | Intervention Type: DRUG; Name: 6% Hypertonic Saline (HS), 4mL; Assigned to Arm(s): Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS), 4mL; Assigned to Arm(s): Isotonic Saline
D: Arm Label: 7% Hypertonic saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hypertonic saline | Arm Label: Hypertonic xylitol; Type: EXPERIMENTAL; Interventions: Drug: Xylitol | Intervention Type: DRUG; Name: Xylitol; Assigned to Arm(s): Hypertonic xylitol | Intervention Type: DRUG; Name: Hypertonic saline; Assigned to Arm(s): 7% Hypertonic saline

Answer: C